InflaRx (IFRX) Change in Accured Expenses (2019 - 2026)
InflaRx (IFRX) posted Change in Accured Expenses of $33932.9 for Q1 2026, up 68.01% sequentially from $20197.3 in Q4 2025, and down 30.32% YoY from $48697.0 in Q1 2025.
InflaRx (IFRX) Change in Accured Expenses (2019 - 2026) Analysis & Trends
InflaRx has reported Change in Accured Expenses for 8 years, with the latest figure at $33932.9 in Q1 2026.
- Quarterly Change in Accured Expenses fell 30.32% year-over-year to $33932.9 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46329.1 (up 101.65% YoY) and the FY2025 annual result came in at $64862.5, up 102.32% from the prior year.
- Change in Accured Expenses advanced to $33932.9 in Q1 2026 per IFRX's latest filing, from $20197.3 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $3.1 million in Q3 2023 and troughed at -$3.0 million in Q2 2024.
- A 5-year average of $17920.1 and a median of $17158.4 in 2023 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses surged 23555.74% in 2023, then slumped 6270.46% in 2024.
- Over 5 years, Change in Accured Expenses stood at $4429.9 in 2022, then sank by 3871.86% to -$167090.2 in 2023, then jumped by 141.74% to $69736.5 in 2024, then slumped by 71.04% to $20197.3 in 2025, then jumped by 68.01% to $33932.9 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $33932.9, $20197.3, and -$23391.6 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | -18,206.07 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33,932.89 |
| Mar 31, 2026 | 33,932.89 |
| Dec 31, 2025 | 20,197.32 |
| Dec 31, 2025 | 20,197.32 |
| Sep 30, 2025 | -23,391.62 |
| Sep 30, 2025 | -23,391.62 |
| Jun 30, 2025 | 15,590.48 |
| Jun 30, 2025 | 15,590.48 |
| Mar 31, 2025 | 48,696.99 |
| Mar 31, 2025 | 48,696.99 |
| Dec 31, 2024 | 69,736.54 |
| Dec 31, 2024 | 69,736.54 |
| Sep 30, 2024 | 68,044.58 |
| Sep 30, 2024 | 68,044.58 |
| Jun 30, 2024 | -2.99 Mn |
| Jun 30, 2024 | -2.99 Mn |
| Mar 31, 2024 | 67,807.44 |
| Mar 31, 2024 | 67,807.44 |
| Dec 31, 2023 | -167,090.24 |
| Dec 31, 2023 | -167,090.24 |